Halozyme(HALO) - 2023 Q4 - Annual Results

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of$ 535-585 Million, Representing YOY Growth of 26- 37% and Non- GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41% Fourth Quarter Revenue Increased 27% YOY to$ 230 million; GAAP Diluted EPS of $0.65 and Non- GAAP Diluted EPS of$ 0.82 1 SAN DIEGO, February 20, 2024 -- Halozyme Therapeutics, ...